Sugi Predict

Sugi Predict / Compounds / SCHEMBL7056630

SCHEMBL7056630

SCHEMBL7056630

O=S(=O)(O)CC1CCC2(CC1)OCCO2

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ INPP5A Q14642 1/20 0.40
▸ LMNA P02545 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ ALDH1A1 P00352 7/20 0.35
▸ TSHR P16473 2/20 0.35
▸ HPGD P15428 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ KMT2A Q03164 3/20 0.33
▸ GPR119 Q8TDV5 1/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ CYP2C19 P33261 2/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ POLB P06746 1/20 0.32
▸ GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3309558 0.81 MAPK1 (0.38) LMNAMAPK1ALDH1A1TSHRHPGD
SCHEMBL3844065 0.79 GPR119 (0.41) LMNAMAPK1ALDH1A1TSHRHPGD
SCHEMBL87245 0.77 POLB (0.42) LMNAMAPK1ALDH1A1TSHRHPGD
SCHEMBL28870877 0.74 LMNA (0.37) LMNAMAPK1ALDH1A1TSHRHPGD
SCHEMBL14381326 0.74 LMNA (0.34) LMNAMAPK1ALDH1A1TSHRHPGD
SCHEMBL23151911 0.74 INPP5A (0.44) INPP5A
SCHEMBL29271491 0.74 INPP5A (0.44) INPP5A
SCHEMBL9099973 0.73 INPP5A (0.62) INPP5ALMNATSHRCYP2C19
SCHEMBL7931443 0.73 — —
SCHEMBL7055111 0.73 INPP5A (0.37) INPP5AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624004-B2 Opioid receptor agonist, preparation method therefor and pharmaceutical use thereof FUDAN UNIVERSITY (CN) 2026-05-12 — — US disclosed
CN-111699176-B Quinazolinones as PARP14 inhibitors 里邦医疗公司 2025-02-14 — — CN disclosed
CN-112442050-B RET inhibitor, pharmaceutical composition and application thereof 广东东阳光药业股份有限公司 2024-08-09 — — CN disclosed
CN-118027041-A BTK inhibitor ring derivative and preparation method and pharmaceutical application thereof 西藏海思科制药有限公司 2024-05-14 — — CN disclosed
CN-110799190-B Heterocyclic compounds 卡都瑞恩医药有限公司 2024-04-19 — — CN disclosed
CN-113365632-B Aminopyrimidine compounds 卡都瑞恩医药有限公司 2024-03-08 — — CN disclosed
CN-113544130-B BTK inhibitor ring derivative and preparation method and pharmaceutical application thereof 西藏海思科制药有限公司 2024-01-09 — — CN disclosed
CN-116583287-A Pyridazinone heterocyclic compound, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2023-08-11 — — CN disclosed
US-20230027752-A1 OPIOID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF FUDAN UNIVERSITY (CN) 2023-01-26 — — US disclosed
CN-111233863-B Hydroxyl purine compound and application thereof 广东众生睿创生物科技有限公司 2022-10-25 — — CN disclosed
EP-1068208-B1 AZATRICYCLO[3.3.1.1] DECANE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM TARGACEPT INC (US) 2003-05-14 — — EP disclosed
US-6417359-B1 1-AZAADAMANTANE DERIVATIVES; NICOTINIC CHOLINERGIC RECEPTOR DRUGS; NEUROPROTECTIVE AGENTS; NERVOUS SYSTEM, PSYCHOLOGICAL, AND GLANDULAR DISORDERS; SIDE EFFECT REDUCTION TARGACEPT, INC. 2002-07-09 — — US disclosed
US-6211372-B1 THERAPY FOR NERVOUS SYSTEM DISORDERS CROOKS PETER ANTHONY (US) 2001-04-03 — — US disclosed
EP-1068208-A1 AZATRICYCLO[3.3.1.1] DECANE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM R.J. REYNOLDS TOBACCO COMPANY (US) 2001-01-17 — — EP disclosed
EP-1066287-A1 AZATRICYCLIC COMPOUNDS R.J. REYNOLDS TOBACCO COMPANY (US) 2001-01-10 — — EP disclosed
US-6057446-A Certain 1-aza-tricyclo [3.3.1-13,7 ] decane compounds TARGACEPT, INC., A CORPORATION OF DELAWARE 2000-05-02 — — US disclosed
US-5986100-A 1-AZA-2-(3-PYRIDYL)-1-AZATRICYCLO(3.3.1.1 3,7)DECANE NICOTINIC CHOLINERGIC AGENTS TARGACEPT, INC. 1999-11-16 — — US disclosed
WO-1999051602-A1 AZATRICYCLO[3.3.1.1] DECANE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM R.J. REYNOLDS TOBACCO COMPANY (US) 1999-10-14 — — WO disclosed
WO-1999051601-A1 AZATRICYCLIC COMPOUNDS R.J. REYNOLDS TOBACCO COMPANY (US) 1999-10-14 — — WO disclosed
US-5952339-A Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release TARGACEPT, INC. 1999-09-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12624004-B2 Opioid receptor agonist, preparation method therefor and pharmaceutical use thereof OPRM1, OPRD1, OPRK1 INPP5A 1728/4885LMNA 4332/4885MAPK1 1360/4885
US-20230027752-A1 OPIOID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF OPRM1, OPRD1, OPRL1 INPP5A 1048/4885LMNA 4419/4885MAPK1 1366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.